



an Open Access Journal by MDPI

## Focus on Antimicrobial Resistance: Research and Recent Advances

Guest Editors:

### Dr. Laura Morelli

Department of Medical  
Biotechnology and Translational  
Medicine, University of Milan, Via  
Saldini 50, 20133 Milan, Italy

### Dr. Giuseppe D'Orazio

Department of Chemistry,  
University of Milan, 20133 Milan,  
Italy

### Dr. Federica Compostella

Department of Medical  
Biotechnology and Translational  
Medicine, University of Milan, Via  
Saldini 50, 20133 Milano, Italy

Deadline for manuscript  
submissions:

**closed (29 February 2024)**

### Message from the Guest Editors

Public health is worldwide threatened by the phenomenon of antimicrobial resistance (AMR), and in particular, by the emergence of new multi-resistant bacterial strains. The strategy to be adopted to prevent, reduce, and mitigate AMR should include a multi-sectoral approach, able to integrate preventive strategies (i.e., vaccines, diagnostic tools) with innovative and effective therapies (i.e., novel antibiotics, monoclonal antibodies, bacteriophages, microbiota).

To this aim, the Special Issue “Focus on Antimicrobial Resistance: research and recent advances” welcomes any contribution in the following research areas that tackle AMR from different perspectives:

- Potential targets for antimicrobial drug development;
- Novel antimicrobial leads;
- Next-generation vaccines against drug-resistant pathogens;
- Microbiota-based strategies to prevent infections;
- Diagnostic methods for molecular detection of resistance determinants;
- Use of surrogate organisms (i.e., Zebrafish, *Caenorhabditis elegans*, etc.) as simpler models to elucidate host–pathogen interactions;
- Omics technologies for the study of AMR;
- Computational analysis of host-pathogen interaction networks.



[mdpi.com/si/165654](https://mdpi.com/si/165654)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)